Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress
Kevin H.M. Kuo(University Health Network), Elliott Vichinsky(Unknown), Megan T. Lynch(University of Maryland, Baltimore), Li Liu(Third Affiliated Hospital of Guangzhou Medical University), Katrin Uhlig(Tufts Medical Center), D. Mark Layton(Imperial College Healthcare NHS Trust)
Cited by 2
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Graft Use in Transvaginal Pelvic Organ Prolapse Repair
|Obstetrics and Gynecology|2008|163
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162